World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
61
Citations
10213
World Ranking
11596
National Ranking
319

Carleen Cullinane publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Carleen Cullinane sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 206 publications — 52nd percentile

52% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Carleen Cullinane D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Carleen Cullinane sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 61 D-Index — 44th percentile

44% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Carleen Cullinane is affiliated with the Peter MacCallum Cancer Centre in Australia and has focused their research primarily in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their work encompasses significant contributions to Molecular Biology, Oncology, Radiology, Nuclear Medicine and Imaging, Epidemiology, and Cancer Research.

The research topics addressed by Cullinane include:

  • Radiopharmaceutical Chemistry and Applications
  • Peptidase Inhibition and Analysis
  • Neuroendocrine Tumor Research Advances
  • Lung Cancer Research Studies
  • Cancer therapeutics and mechanisms
  • CAR-T cell therapy research
  • DNA Repair Mechanisms

Among their recent publications are the following papers:

  • "Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP," 2020, Scientific Reports
  • "Peptide Receptor Radionuclide Therapy with 67Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model," 2020, Journal of Nuclear Medicine

Other notable papers in which they contributed as an author or co-author include:

  • "CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer," 2020, Nature Communications
  • "EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma," 2020, Journal of Investigative Dermatology
  • "The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer," 2020, British Journal of Cancer

Cullinane has collaborated frequently with other researchers, including:

  • Rodney J. Hicks
  • Jessica Van Zuylekom
  • Peter Roselt
  • Paul S. Donnelly
  • Grant A. McArthur

Their work has been published in several recurring venues, principally:

  • Journal of Medicinal Chemistry
  • Cancer Research
  • Nature Communications
  • Journal of Nuclear Medicine
  • Chemical Science

Best Publications

  • Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.

    Megan J Bywater;Gretchen Poortinga;Gretchen Poortinga;Elaine Sanij;Elaine Sanij;Nadine Hein

  • An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer

    Marian L. Burr;Marian L. Burr;Marian L. Burr;Christina E. Sparbier;Christina E. Sparbier;Kah Lok Chan;Kah Lok Chan;Yih-Chih Chan

  • Toxicity of cucurbit[7]uril and cucurbit[8]uril: an exploratory in vitro and in vivo study

    Vanya D. Uzunova;Carleen Cullinane;Klaudia Brix;Werner M. Nau

  • UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas

    Stephen Q. Wong;Kelly Waldeck;Ismael A. Vergara;Jan Schröder;Jan Schröder;Jan Schröder

  • Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation

    David Shi Hao Liu;Cuong Phu Duong;Sue Haupt;Karen G Montgomery

  • Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

    Tiffany J. Parmenter;Margarete Kleinschmidt;Kathryn M. Kinross;Simon T. Bond

  • Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.

    Richard J. Young;Kelly Waldeck;Claire Martin;Jung H. Foo

  • An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.

    Kathryn M Kinross;Karen G Montgomery;Margarete Kleinschmidt;Paul Waring

  • CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer.

    Elaine Sanij;Elaine Sanij;Katherine M. Hannan;Katherine M. Hannan;Jiachen Xuan;Jiachen Xuan;Shunfei Yan;Shunfei Yan

  • Studies of a cobalt(III) complex of the MMP inhibitor marimastat: a potential hypoxia-activated prodrug.

    Timothy W. Failes;Carleen Cullinane;Connie I. Diakos;Natsuho Yamamoto

  • EGFR blockade with ZD1839 (“Iressa”) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma

    Benjamin Solomon;Jim Hagekyriakou;Melanie K Trivett;Steven A Stacker

  • Multi-nuclear platinum complexes encapsulated in cucurbit[n]uril as an approach to reduce toxicity in cancer treatment

    Nial J. Wheate;Anthony I. Day;Rodney J. Blanch;Alan P. Arnold

  • Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results.

    Gerald Reischl;Donna S Dorow;Carleen Cullinane;Andrew Katsifis

  • PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate

    Brett M. Paterson;Peter Roselt;Delphine Denoyer;Carleen Cullinane;Carleen Cullinane

  • Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.

    George H. Au-Yeung;George H. Au-Yeung;Franziska Lang;Walid J Azar;Chris Mitchell

  • An In vivo Tumor Model Exploiting Metabolic Response as a Biomarker for Targeted Drug Development

    Carleen Cullinane;Donna S. Dorow;Maya Kansara;Nelly Conus

  • Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma

    Jennifer R Devlin;Katherine M Hannan;Katherine M Hannan;Nadine Hein;Nadine Hein;Carleen M Cullinane;Carleen M Cullinane

  • LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin

    Prue A Cowin;Joshy George;Joshy George;Sian Fereday;Elizabeth Loehrer

  • Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer

    Dariush Etemadmoghadam;George Au-Yeung;Meaghan Wall;Chris Mitchell

  • Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian Cancer

    Dariush Etemadmoghadam;Joshy George;Joshy George;Prue A. Cowin;Carleen Cullinane

Frequent Co-Authors

Grant A. McArthur
Grant A. McArthur Peter MacCallum Cancer Centre
Rodney J. Hicks
Rodney J. Hicks Peter MacCallum Cancer Centre
Richard B. Pearson
Richard B. Pearson Peter MacCallum Cancer Centre
Ricky W. Johnstone
Ricky W. Johnstone Peter MacCallum Cancer Centre
Ross D. Hannan
Ross D. Hannan Australian National University
Paul S. Donnelly
Paul S. Donnelly University of Melbourne
David D.L. Bowtell
David D.L. Bowtell Peter MacCallum Cancer Centre
Peter Hersey
Peter Hersey University of Sydney
Wayne A. Phillips
Wayne A. Phillips Peter MacCallum Cancer Centre
Anthony T. Papenfuss
Anthony T. Papenfuss Walter and Eliza Hall Institute of Medical Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Carleen Cullinane

Trending Scientists

Recently Published Articles